Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Gross Profit (2016 - 2025)

Historic Gross Profit for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $9.5 million.

  • Protalix BioTherapeutics' Gross Profit fell 59.47% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 11724.26%. This contributed to the annual value of $29.1 million for FY2024, which is 3159.58% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Gross Profit stood at $9.5 million for Q3 2025, which was down 59.47% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Gross Profit ranged from a high of $28.9 million in Q2 2023 and a low of $1.1 million during Q1 2024
  • Its 5-year average for Gross Profit is $7.5 million, with a median of $6.5 million in 2023.
  • Over the last 5 years, Protalix BioTherapeutics' Gross Profit had its largest YoY gain of 77926.38% in 2024, and its largest YoY loss of 8610.99% in 2024.
  • Protalix BioTherapeutics' Gross Profit (Quarter) stood at $5.4 million in 2021, then rose by 15.16% to $6.2 million in 2022, then plummeted by 73.79% to $1.6 million in 2023, then surged by 779.26% to $14.3 million in 2024, then tumbled by 33.53% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, $9.8 million for Q2 2025, and $1.9 million during Q1 2025.